Is CLBS or JEPQ a better dividend investment in 2026?

CLBS currently yields 131.33% with a 5% 5-year dividend growth rate. JEPQ yields 11.10% with 5% growth. The better choice depends on your goal: CLBS offers higher current income.

What is the dividend yield difference between CLBS and JEPQ?

CLBS has a forward dividend yield of 131.33% ($0.56/share annually). JEPQ yields 11.10% ($6.16/share annually). The yield gap is 120.23 percentage points.

Home › Compare › CLBS vs JEPQ

CLBS vs JEPQ: Dividend Comparison 2026

CLBS yields 131.33% · JEPQ yields 11.10%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CLBS wins by $12.95M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CLBS

● Live price

131.33%

Share price

$0.43

Annual div

$0.56

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$12.99M

Annual income

$5,201,713.69

Full CLBS calculator →

JEPQ

JPMorgan Nasdaq Equity Premium Income ETF

● Live price

11.10%

Share price

$55.52

Annual div

$6.16

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.8K

Annual income

$2,152.59

Full JEPQ calculator →

Portfolio growth — CLBS vs JEPQ

📍 CLBS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CLBS	JEPQ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CLBS + JEPQ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CLBS pays

JEPQ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLBS

Annual income on $10K today (after 15% tax)

$11,163.23/yr

After 10yr DRIP, annual income (after tax)

$4,421,456.64/yr

JEPQ

Annual income on $10K today (after 15% tax)

$943.83/yr

After 10yr DRIP, annual income (after tax)

$1,829.70/yr

At 15% tax rate, CLBS beats the other by $4,419,626.94/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLBS + JEPQ for your $10,000?

CLBS: 50%JEPQ: 50%

100% JEPQ50/50100% CLBS

Portfolio after 10yr

$6.52M

Annual income

$2,601,933.13/yr

Blended yield

39.91%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLBS buys

JEPQ buys

No recent congressional trades found for CLBS or JEPQ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCLBSJEPQ

Forward yield	131.33% ✓	11.10%
Annual dividend / share	$0.56	$6.16 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$12.99M	$44.8K ✓
Annual income after 10y	$5,201,713.69 ✓	$2,152.59
Total dividends collected	$11.90M	$16.3K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: CLBS vs JEPQ ($10,000, DRIP)

Year	CLBS Portfolio	CLBS Income/yr	JEPQ Portfolio	JEPQ Income/yr	Gap
1← crossover	$23,833	$13,133.21	$11,930	$1,110.39	+$11.9K → CLBS
2	$54,754	$29,252.94	$14,133	$1,224.34	+$40.6K → CLBS
3	$121,396	$62,809.15	$16,632	$1,340.46	+$104.8K → CLBS
4	$260,039	$130,144.39	$19,454	$1,457.97	+$240.6K → CLBS
5	$538,781	$260,539.45	$22,626	$1,576.08	+$516.2K → CLBS
6	$1,080,999	$504,503.28	$26,175	$1,694.09	+$1.05M → CLBS
7	$2,102,673	$946,004.75	$30,133	$1,811.32	+$2.07M → CLBS
8	$3,969,574	$1,719,713.85	$34,531	$1,927.17	+$3.94M → CLBS
9	$7,281,647	$3,034,202.37	$39,403	$2,041.08	+$7.24M → CLBS
10	$12,993,076	$5,201,713.69	$44,787	$2,152.59	+$12.95M → CLBS

CLBS vs JEPQ: Complete Analysis 2026

CLBS — Stock

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Full CLBS Calculator →

JEPQ — ETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →

📬

Get this CLBS vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLBS vs SCHD CLBS vs JEPI CLBS vs O CLBS vs KO CLBS vs MAIN CLBS vs XYLD CLBS vs QYLD CLBS vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.